Tiziana Life Sciences Interview to Air on Bloomberg Television U.S. on the RedChip Money Report
Tiziana Life Sci PLC (TILS.L) TLSA interview on Bloomberg TV on 8th May 2021
Tiziana Life Sci PLC (TILS.L) B. Riley Virtual Neuroscience Investor Conference
Tiziana Life Sciences to participate in a Fireside Chat on 28 April 2021 at 10:30 a.m. EDT
Tiziana Life Sci PLC (TILS.L) Announces Plans to List Accustem Sciences Limited in the U.S.
NEW YORK and LONDON, April 13, 2021 – Tiziana Life Sciences plc (NASDAQ: TLSA; LSE: TILS), today announced that its former subsidiary, Accustem Sciences Limited (“Accustem”), intends to file a
Tiziana Life Sci PLC (TILS.L) P2 Study in Moderate to Severe Covid-19 Patients
Tiziana Plans Phase 2 Clinical Study in Moderate to Severe Covid-19 Patients with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody
Tiziana Life Sciences plc (TILS.L) Chairman of Tiziana to give interview on Bloomberg
Gabriele Cerrone, Chairman of Tiziana Life Sciences, to give an interview on Bloomberg Television US at 1:20 PM ET Today
Tiziana Life Sci PLC (TILS.L) Tiziana Interview to Air on Bloomberg TV
Tiziana Life Sciences Interview to Air on Bloomberg Television US on the RedChip Money Report
Tiziana Life Sci PLC (TILS.L) Tiziana at BIO CEO & Investor Digital Conference
Tiziana Life Sciences to Present at the BIO CEO & Investor Digital Conference
Tiziana Life Sci PLC (TILS.L) Appointment of Dr Thomas Adams, Ph.D. as an executive director
NEW YORK and LONDON – February 5, 2021 (GLOBE NEWSWIRE) – Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative
Tiziana Life Sci PLC (TILS.L) CEO exclusive interview to discuss COVID-19 Trial
Tiziana Life Sciences CEO Discusses COVID-19 Trial Data in Exclusive Interview
Tiziana Life Sci PLC (TILS.L) Positive Data: Nasal Administration of Foralumab
Tiziana Reports Positive Data from the Clinical Study of Nasal Administration with Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, in COVID-19 Patients in Brazil
Tiziana Life Sci PLC (TILS.Nasdaq.L) Updated corporate presentation
New York/London, 26 January 2021 – Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and
